Alaunos Therapeutics Inc. operates as a clinical stage cellular immuno-oncology company. The Company focuses on the treatment of solid tumors through adoptive TCR-T cell therapy. Alaunos Therapeutics serves customers worldwide.

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

S-3/A | Registration statement for specified transactions by certain issuers (Amendment)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Alaunos Therapeutics (TCRT US)

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

S-3/A | Registration statement for specified transactions by certain issuers (Amendment)

Current Report (Form 8-K | Period ending 2025-08-19)

Quarterly Report (Form 10-Q | Period ending 2025-06-30)

Current Report (Form 8-K | Period ending 2025-07-16)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)